Adaptive Immune Determinants of Viral Clearance and Protection in Mouse Models of SARS-CoV-2

Overview

Journal Sci Immunol

Specialty Allergy & Immunology

Date 2021 Oct 8

PMID 34623900

Citations 119

Authors

Benjamin Israelow

Tianyang Mao

Jonathan Klein

Eric Song

Bridget Menasche

Saad B Omer

Akiko Iwasaki

Affiliations

Soon will be listed here.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 160 million infections and more than 3 million deaths worldwide. Although effective vaccines are currently being deployed, the adaptive immune determinants that promote viral clearance and confer protection remain poorly defined. Using mouse models of SARS-CoV-2, we demonstrate that both humoral and cellular adaptive immunity contribute to viral clearance in the setting of primary infection. Furthermore, we find that either convalescent mice or mice that receive mRNA vaccination are protected from both homologous infection and infection with a variant of concern, B.1.351. In addition, we find that this protection is largely mediated by antibody response and not cellular immunity. These results highlight the in vivo protective capacity of antibodies generated to both vaccine and natural infection.

Citing Articles

An LNP-mRNA vaccine modulates innate cell trafficking and promotes polyfunctional Th1 CD4 T cell responses to enhance BCG-induced protective immunity against Mycobacterium tuberculosis.

Lukeman H, Al-Wassiti H, Fabb S, Lim L, Wang T, Britton W EBioMedicine. 2025; 113:105599.

PMID: 39955975 PMC: 11871481. DOI: 10.1016/j.ebiom.2025.105599.

Neutralizing antibody responses to three XBB protein vaccines in older adults.

Yang G, Lu M, Chen R, Wang S, Wan S, Song X Signal Transduct Target Ther. 2025; 10(1):48.

PMID: 39894858 PMC: 11788433. DOI: 10.1038/s41392-025-02132-y.

mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice.

Liang X, Yuan Y, Wang J, Tang C, Yang Y, Zhou Y NPJ Vaccines. 2025; 10(1):7.

PMID: 39805865 PMC: 11729908. DOI: 10.1038/s41541-025-01066-4.

The BNT162b2 mRNA vaccine demonstrates reduced age-associated T1 support and .

Brook B, Checkervarty A, Barman S, Sweitzer C, Bosco A, Sherman A iScience. 2024; 27(11):111055.

PMID: 39569372 PMC: 11576392. DOI: 10.1016/j.isci.2024.111055.

mRNA vaccine-induced IgG mediates nasal SARS-CoV-2 clearance in mice.

Fricke C, Ulrich L, Kochmann J, Gergen J, Kovacikova K, Roth N Mol Ther Nucleic Acids. 2024; 35(4):102360.

PMID: 39524696 PMC: 11550364. DOI: 10.1016/j.omtn.2024.102360.

References

Wall E, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C . Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021; 397(10292):2331-2333. PMC: 8175044. DOI: 10.1016/S0140-6736(21)01290-3. View

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

Grifoni A, Weiskopf D, Ramirez S, Mateus J, Dan J, Rydyznski Moderbacher C . Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181(7):1489-1501.e15. PMC: 7237901. DOI: 10.1016/j.cell.2020.05.015. View

Rydyznski Moderbacher C, Ramirez S, Dan J, Grifoni A, Hastie K, Weiskopf D . Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020; 183(4):996-1012.e19. PMC: 7494270. DOI: 10.1016/j.cell.2020.09.038. View

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View

Rodda L, Netland J, Shehata L, Pruner K, Morawski P, Thouvenel C . Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell. 2020; 184(1):169-183.e17. PMC: 7682481. DOI: 10.1016/j.cell.2020.11.029. View

Mulligan M, Lyke K, Kitchin N, Absalon J, Gurtman A, Lockhart S . Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020; 586(7830):589-593. DOI: 10.1038/s41586-020-2639-4. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Zhuang Z, Lai X, Sun J, Chen Z, Zhang Z, Dai J . Mapping and role of T cell response in SARS-CoV-2-infected mice. J Exp Med. 2021; 218(4). PMC: 7814348. DOI: 10.1084/jem.20202187. View

10.

Israelow B, Song E, Mao T, Lu P, Meir A, Liu F . Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J Exp Med. 2020; 217(12). PMC: 7401025. DOI: 10.1084/jem.20201241. View

11.

Baang J, Smith C, Mirabelli C, Valesano A, Manthei D, Bachman M . Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. J Infect Dis. 2020; 223(1):23-27. PMC: 7797758. DOI: 10.1093/infdis/jiaa666. View

12.

Mira E, Yarce O, Ortega C, Fernandez S, Pascual N, Gomez C . Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. J Allergy Clin Immunol Pract. 2020; 8(8):2793-2795. PMC: 7345404. DOI: 10.1016/j.jaip.2020.06.046. View

13.

Winkler E, Bailey A, Kafai N, Nair S, McCune B, Yu J . SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020; 21(11):1327-1335. PMC: 7578095. DOI: 10.1038/s41590-020-0778-2. View

14.

Garcia-Beltran W, Lam E, St Denis K, Nitido A, Garcia Z, Hauser B . Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184(9):2372-2383.e9. PMC: 7953441. DOI: 10.1016/j.cell.2021.03.013. View

15.

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View

16.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View

17.

Corbett K, Edwards D, Leist S, Abiona O, Boyoglu-Barnum S, Gillespie R . SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020; 586(7830):567-571. PMC: 7581537. DOI: 10.1038/s41586-020-2622-0. View

18.

Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M . A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; 26(7):1033-1036. PMC: 8183627. DOI: 10.1038/s41591-020-0913-5. View

19.

Tan A, Linster M, Tan C, Bert N, Chia W, Kunasegaran K . Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021; 34(6):108728. PMC: 7826084. DOI: 10.1016/j.celrep.2021.108728. View

20.

Zhao J, Zhao J, Mangalam A, Channappanavar R, Fett C, Meyerholz D . Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016; 44(6):1379-91. PMC: 4917442. DOI: 10.1016/j.immuni.2016.05.006. View